Stock ARNO THERAPEUTICS INC(NDA)
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Arno Therapeutics Inc(NDA) OTC Bulletin Board

Equities

US0425641042

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for Arno Therapeutics Inc(NDA)
2017 Arno Therapeutics, Inc. Terminates Licensing Agreement with Ohio State University CI
2017 Arno Therapeutics Seeks Acquisitions CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arno Therapeutics, Inc. Terminates Licensing Agreement with Ohio State University
CI
Arno Therapeutics Seeks Acquisitions
CI
Arno Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016
CI
Arno Therapeutics, Inc. announced that it has received $2.725498 million in funding from Pontifax Ltd., OPKO Health, Inc., Perceptive Advisors LLC, Commercial Street Capital, LLC, Bonderman Family Limited Partnership, Auriga Capital Management, LLC
CI
Arno Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016
CI
Arno Therapeutics, Inc. Updates Clinical Development of Onapristone Plus Zytiga
CI
Arno Therapeutics, Inc. announced that it expects to receive $2.98 million in funding from a group of investors
CI
Arno Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016
CI
Arno Therapeutics, Inc. Announces Consolidated Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2015
CI
Arno Therapeutics, Inc. Appoints Jay Moorin to its Board of Directors
CI
Arno Therapeutics, Inc. announced that it has received $5.28 million in funding from Commercial Street Capital, LLC, and other investors.
CI
Arno Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
CI
Arno Therapeutics, Inc. Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains
CI
Arno Therapeutics, Inc. announced that it expects to receive $2.1 million in funding from Commercial Street Capital, LLC and other investors.
CI
Arno Therapeutics, Inc. Announces Data Demonstrates Novel Antimicrobial Activity of AR-12
CI
Arno Therapeutics, Inc. Announces Resignation of Lawrence A. Kenyon as Chief Operating Officer and Chief Financial Officer, Effective September 15, 2015
CI
Arno Therapeutics, Inc. Receives Authorization to Proceed with Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer
CI
Arno Therapeutics, Inc. Announces Unaudited Financial Results for the Second Quarter and Six Months Ended June 30, 2015
CI
Arno Therapeutics, Inc. Announces Cooperative Research and Development Agreement with US Army Medical Research Institute of Infectious Diseases to Test Antiviral Activity of AR-12
CI
Arno Therapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARNI Stock
  4. Stock
  5. News Arno Therapeutics Inc(NDA)